Letter Regarding “Is It Safe to Give Meloxicam or Celecoxib to Chronically Anticoagulated Patients Following Primary Total Knee Arthroplasty?”
The Journal of Arthroplasty · 2026-07 · 41 (7) · e74-e75
DOI: 10.1016/j.arth.2026.01.075 ↗Kurz gefasst
Leserbrief in der Zeitschrift The Journal of Arthroplasty, 2026-07. Verfasst von Chase W Smitterberg und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, Baltimore, Maryland. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- The Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, Baltimore, Maryland.
Zitieren
APA
Smitterberg, C. W., & Mont, M. A. (2026). Letter Regarding “Is It Safe to Give Meloxicam or Celecoxib to Chronically Anticoagulated Patients Following Primary Total Knee Arthroplasty?”. The Journal of Arthroplasty, 41(7), e74-e75. https://doi.org/10.1016/j.arth.2026.01.075
Vancouver
Smitterberg CW, Mont MA. Letter Regarding “Is It Safe to Give Meloxicam or Celecoxib to Chronically Anticoagulated Patients Following Primary Total Knee Arthroplasty?”. The Journal of Arthroplasty. 2026;41(7):e74-e75. doi:10.1016/j.arth.2026.01.075
BibTeX
@article{Smitterberg2026,
author = {Smitterberg, Chase W and Mont, Michael A},
title = {Letter Regarding “Is It Safe to Give Meloxicam or Celecoxib to Chronically Anticoagulated Patients Following Primary Total Knee Arthroplasty?”},
journal = {The Journal of Arthroplasty},
year = {2026},
volume = {41},
number = {7},
pages = {e74--e75},
doi = {10.1016/j.arth.2026.01.075}
}
EUVIMED